Transplanted patient with late post-transplant linfoproliferative disease (PTLD) and graft collapsing glomerulopathy

Luciano Leguizamón Programa de Trasplante Renal, Hospital de Clínicas José de San Martí, Buenos Aires
Pablo Barbero Programa de Trasplante Renal, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires
Lilian Martinez Programa de Trasplante Renal, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires
Gerardo Gutiérrez Avilés División Nefrología, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires
Hernán Sarzuri Marca División Nefrología, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires
Fernando Segovia División Nefrología, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires
Laura Idiarte Programa de Trasplante Renal, HHospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires

Keywords: lymphoproliferative diseases, kidney transplant, post-transplant disorders, collapsing glomerulopathy, graft rejection, focal segmental glomerulosclerosis

References

Allen UD. Clinical features and Diagnosis evaluation of post-transplant lymphoproliferative disease. En: Dharnidharka VR, Green M, Webber SA, eds. Posttransplant

lymphoproliferative disorders. Heidelberg, Springer, 2010; p. 69-88.

Ashrafi F, Shahidi S, Ebrahimi Z, Mortazavi M. Outcome of rapamycin therapy for post-transplant-lymphoproliferative disorder after kidney transplantation: case series. Int J Hematol Oncol Stem Cell Res. 2015;9(1):26-32.

Bakker NA, Pruim J, de Graaf W, van Son WJ, van der Jagt EJ, van Imhoff GW. PTLD visualization by FDG-PET: improved detection of extranodal localizations. Am J Transplant. 2006;6(8):1984-5.

Bowden RA, Ljungman P, Snydman DR, eds. Transplant infections. 3rd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2010.

Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol. 2007;18(4):1046-56.

Ferreira H, Bustorff M, Santos J, Ferreira I, Sampaio S, Salomé I, et al. Post-transplant Lymphoproliferative Disorder: A Single-Center Experience. Transplant Proc. 2015;47(4):981-4.

Feucht HE. Complement C4d in graft capillaries the missing link in the recognition of humoral alloreactivity. Am J Transplant. 2003;3(6):646-52.

Gupta R, Sharma A, Mahanta PJ, Agarwal SK, Dinda AK. Focal and segmental glomerulosclerosis in renal allograft recipients: a clinico-pathologic study of 37 cases. Saudi J Kidney Dis Transpl. 2013;24(1):8-14.

Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation. 1990;49(1):85-91.

Sureshkumar KK, Dosani I, Jasnosz KM, Arora S. De Novo Collapsing Glomerulopathy: An Unusual Cause of Early Graft Failure following Kidney Transplantation. Case Rep Transplant. 2001;2001: 263970.

Kasiske BL, Kukla A, Thomas D, Wood Ives J, Snyder JJ, Qiu Y, et al. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses. Am J Kidney Dis. 2011;58(6):971-80.

Letavernier E, Bruneval P, Mandet C, Duong Van Huyen JP, Péraldi MN, Helal I, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol. 2007;2(2):326-33.

Meehan SM, Pascual M, Williams WW, Tolkoff-Rubin N, Delmonico FL, et al. De novo collapsing glomerulopathy in renal allografts. Transplantation. 1998;65(9):1192-7.

Mohamed N, Goldstein J, Schiff J, John R. Collapsing glomerulopathy following anthracycline therapy. Am J Kidney Dis. 2013;61(5):778-81.

Mubarak M. Collapsing focal segmental glomerulosclerosis: Increasing the awareness. J Nephropathol. 2012;1(2):77-80.

Mucha K, Foroncewicz B, Ziarkiewicz-Wróblewska B, Krawczyk M, Lerut J, Paczek L. Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant. 2010;25(7):2089-98.

Serre JE, Michonneau D, Bachy E, Noël LH, Dubo V, Suberbielle C, et al. Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. Kidney Int. 2014;85(1):182-90.

Steven H. Swerdlow. Pathology. En: VR Dharnidharka, M Green, SA Webber, eds. Post-transplant lymphoproliferative disorders. Heidelberg, Springer, 2010; p. 89-104.

Stokes MB, Davis CL, Alpers CE. Collapsing glomerulopathy in renal allografts: a morphological pattern with diverse clinicopathologic associations. Am J Kidney Dis. 1999;33(4):658-66.

Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphopro-liferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71(8):1076-88.

Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant. 2007;7(2):408-15.

Trpkov K, Campbell P, Pazderka F, Cockfield S, Solez K, Halloran PF. Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema. Transplantation. 1996;61(11):1586-92.

Zou Y, Stastny P, Süsal C, Döhler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med. 2007;357(13):1293-300.

Published

2016-03-15

How to Cite

Leguizamón L, Barbero P, Martinez L, Gutiérrez Avilés G, Sarzuri Marca H, Segovia F, Idiarte L. Transplanted patient with late post-transplant linfoproliferative disease (PTLD) and graft collapsing glomerulopathy. Rev Nefrol Dial Traspl. [Internet]. 2016Mar.15 [cited 2024Nov.24];36(1):54-1. Available from: http://revistarenal.org.ar/index.php/rndt/article/view/55